Trials / Completed
CompletedNCT04450394
A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 278 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3209590 | Administered SC |
| DRUG | Insulin Degludec | Administered SC |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2021-10-08
- Completion
- 2021-10-08
- First posted
- 2020-06-29
- Last updated
- 2022-11-02
- Results posted
- 2022-11-02
Locations
64 sites across 5 countries: United States, Argentina, Germany, Poland, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04450394. Inclusion in this directory is not an endorsement.